Navigation Links
Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Date:7/5/2012

HELSINKI, Finland, July 5, 2012 /PRNewswire/ --

Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB). Bringing together a group of recognized leading experts in Oncology and Oncolytic Virus drug development, combining a wealth of clinical, strategic, and scientific experience in cancer drug development, immunotherapy, and oncolytic viruses, the CAB is well suited to support the company's innovative development strategy.

"Oncolytic viruses have the potential to become an important next-generation modality of cancer therapeutics" says Kapil Dhingra, consultant to the company and member of the Clinical Advisory Board.

"I am very pleased to be able to work together with this distinguished group of experts. They are already making a significant and very valuable contribution to our strategy as well as brainstorming novel approaches, and being very pragmatic and feasibility-oriented", says Dr. Mikael von Euler, CMO and Head of Research at Oncos who was recently appointed as Chairman of the Clinical Advisory Board.

Dr. von Euler is pleased to include the following leading oncology experts into the CAB: Dr. Kapil Dhingra, former Head of Roche Global Oncology Clinical Development; Dr. Lee Helman, Head of Molecular Oncology Section at the National Cancer Institute (NCI) and Co-founder of the Sarcoma Alliance for Research Through Collaboration (SARC)  in the USA; Dr. Kevin Harrington of the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in London, one of the most experienced European investigators in oncolytic virus trials; Dr. Eva Galanis of Mayo Clinic, a leading scientist in oncolytic viruses in the USA; Dr. Luca Gianni, Director of Medical Oncology at the San Raffaele Hospital in Milan and the 2011 ASCO recipient of the Gianni Bonadonna Breast Cancer Award for his achievements in advancing the field of breast cancer research and Dr. Elke Jäger of the Nordwest Krankenhaus in Frankfurt, a distinguished cancer immunotherapy opinion leader in Europe.

"Our CAB has already made a significant contribution to our clinical development strategy", comments Pekka Simula, CEO and Co-Founder of Oncos Therapeutics. "It's a thrilling experience for the entire Oncosteam to be executing the strategic ideas of such talented oncology experts."

About Oncos Therapeutics

Oncos Therapeutics, based in Helsinki, Finland, develops novel cancer therapies based on its next generation oncolytic viruses. Its ongoing clinical development program of the lead virus CGTG-102 is based on clinical experience from an experimental treatment program with ten different oncolytic viruses, and is planned to expand into several countries in the near future. For more information about Oncos visit http://www.oncos.com.


'/>"/>
SOURCE Oncos Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
2. OncoSec Medical Issues Letter to Shareholders
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
5. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
9. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
10. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
11. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... 2017 RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... Patent Office (JPO) for the composition of matter ... for the treatment or prevention of fibrotic disorders, ... proliferative retinopathy (Japanese Patent #: 6060071).  This patent ...
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, Inc., ... company, is pleased to announce that the Company ... of Panther Orthopedics, Inc., a San ... fixation solutions for orthopedic extremity applications.  ... expand rapidly, primarily due to procedure volume growth, ...
Breaking Medicine Technology:
(Date:3/28/2017)... VA (PRWEB) , ... March 28, 2017 , ... The ... Still, MHA, FRBMA, has begun to serve as its new executive director. Mr. Still ... the Executive Search Committee. , “Bob, as he is known to our members, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , ... biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based ... Attendance uses biometric face recognition to enable users to check in and out ...
(Date:3/28/2017)... St. Petersburg Florida (PRWEB) , ... March 28, 2017 , ... ... U.S. Marine Corp to raise money to for the Toys for Tots Literacy Campaign ... a federal budget in excess of $70 billion, the U.S. ranks at number 14 ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant ... Surgical, Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to ... adds to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. ...
(Date:3/28/2017)... ... ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in women's ... loss. Although hair transplant procedures can be seen as more of a man’s issue, ... two reasons a woman may see her hair thinning. , “We are used to ...
Breaking Medicine News(10 mins):